Back to mobile site

H.C. Wainwright Reiterates Buy Rating on Outlook Therapeutics Incs. (OTLK)

November 29, 2024 6:32 AM EST Send to a Friend
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating and $30.00 price target on Outlook Therapeutics Incs. (NASDAQ: OTLK).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login